Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sinovac PCV13 · 3 trials · 2 indications
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the difference (Sinovac-PCV13 minus Prevenar 13™) \> -10% for each serotype at 30 days after dose 2.
Non-inferiority criterion: The lower limit of the two-sided 95% CI for the GMC ratio (Sinovac-PCV13/Prevenar 13™) \> 0.5 for each serotype at 30 days after dose 2.
Proportion of serotype-specific IgG concentration ≥0.35 μg/ml
IgG GMC
Incidence of adverse reactions within 30 days after each dose
| Arm | Type | Description |
|---|---|---|
| Sinovac PCV 13 | EXPERIMENTAL | 250 participants aged 2 months (42 to 89 days) will receive 3 doses of Sinovac PCV13 at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months. |
| Prevenar 13™ | ACTIVE_COMPARATOR | 250 participants aged 2 months (42 to 89 days) will receive 3 doses of Prevenar 13™ at approximately 2, 4 and 12-15 months of age.Route of administration is intramuscular injection at anterolateral thigh for infants aged younger than 12 months, and at deltoid muscle of upper arm for children aged older than 12 months. |
| Experimental: Sinovac PCV13 | EXPERIMENTAL | Participants aged 6 weeks-5 years will receive 4 doses of Sinovac PCV13 according to different immunization schedules. |
| Active Comparator: Prevnar® | ACTIVE_COMPARATOR | Participants aged 6 weeks-5 years will receive 4 doses of Prevnar 13® according to different immunization schedules. |
| Infants aged 2 months in experimental group | EXPERIMENTAL | 35 participants aged 2 months will be randomized to receive Sinovac PCV13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months. |
| Infants aged 2 months in control group | ACTIVE_COMPARATOR | 35 participants aged 2 months will be randomized to receive PREVNAR 13. Route of administration is intramuscular injection at anterolateral aspect of thigh; immunization schedule is 4 doses, including 3 doses (two-month interval) in primary vaccination and a booster dose at the age of 12-15 months. |
| Children aged 2-5 years in experimental group | EXPERIMENTAL | 35 children aged 2-5 years will be randomized to receive Sinovac PCV13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old. |
| Children aged 2-5 years in control group | ACTIVE_COMPARATOR | 35 children aged 2-5 years will be randomized to receive PREVNAR 13. The route of administration is intramuscular injection at deltoid muscle of the upper arm, and immunization schedule is 1 dose for children aged 2-5 years old. |
| Name | Type | Description |
|---|---|---|
| Sinovac PCV13 | BIOLOGICAL | One dose of Sinovac PCV13 (0.5ml) was administered at 2, 4, and 12-15 months of age. |
| Prevenar 13™ | BIOLOGICAL | One dose of Prevenar 13™ (0.5ml) was administered at 2, 4, and 12-15 months of age. |
| Prevnar® | BIOLOGICAL | One dose of Prevnar® (0.5 mL) is administered intramuscularly. |
| PREVNAR 13 | BIOLOGICAL | 0.5 mL dose of PREVNAR 13 contains 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides. |
Inclusion Criteria: 1. Health infants aged approximately 2 months (42 to 89 days) 2. Have a parent/legal guardian who has provided written informed consent after being fully informed about the study. 3. Be able to provide the vaccination records since birth. 4. The infant's mother is tested negativ...
Sinovac PCV13 is an investigational 13-valent pneumococcal conjugate vaccine being developed by Sinovac Biotech, Ltd for the prevention of pneumococcal infectious disease. It is a biologic given to healthy volunteers, including infants from about six weeks of age, and is currently in Phase 3 clinical development.
Sinovac PCV13 is being developed for pneumococcal infectious disease, the infections caused by Streptococcus pneumoniae. Its clinical trials enroll healthy volunteers, including infants as young as 42 days, and evaluate the vaccine in that pediatric population. It is investigational and has not been established as a marketed preventive vaccine.
Sinovac PCV13 is being developed by Sinovac Biotech, Ltd, which trades under the ticker SVA. The company sponsors the Phase 3 and earlier clinical trials of the 13-valent pneumococcal conjugate vaccine in infants and young children.
Sinovac PCV13 is in Phase 3 clinical development. Two Phase 3 trials are registered, one recruiting in China and one not yet recruiting in the Philippines, alongside a completed Phase 1b trial. The vaccine remains investigational and is not approved for marketing.
Sinovac PCV13 has three registered trials. NCT06617715 is a recruiting Phase 3 trial in China with 3,080 participants. NCT07593924 is a Phase 3 trial in the Philippines with 500 infants aged 42 to 89 days that is not yet recruiting. NCT06183216 is a completed Phase 1b trial in China with 140 participants.
The Sinovac PCV13 trials are randomized, double-blind, and active-controlled, enrolling healthy volunteers from six weeks of age. Across the three registered studies, total planned enrollment is 3,720 participants. The Phase 3 studies are conducted in China and the Philippines, and the Phase 1b study in China is completed.